Madrigal’s Rezdiffra Continues Its Solid Launch

 
• By Joseph Haas

With $180m in sales during its first nine months on the US market, the first approved MASH drug still tops projections. Madrigal predicts continued growth in 2025, with EU entry expected.

Set of Three Increasing Size Red and White Cartoon Spaceships on Dark Background
Madrigal's Rezdiffra continued its early growth through three quarters on the market • Source: Alamy

More from Earnings

More from Therapy Areas